Avanos Medical (AVNS) Change in Accured Expenses (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Change in Accured Expenses data on file, last reported at -$33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 127.7% year-over-year to -$33.7 million; the trailing twelve-month figure through Mar 2026 stood at -$31.8 million (down 2371.43% YoY), and the FY2025 full-year result was -$12.9 million, down 13.16% from the prior year.
• Change in Accured Expenses fell to -$33.7 million in Q1 2026, from $9.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $17.4 million in Q3 2023 to a low of -$33.7 million in Q1 2026.
• A 5-year average of -$5.5 million and a median of -$7.2 million in 2025 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 3300.0% in 2023 and soared 276.04% in 2024, its largest moves.
• Tracing AVNS's Change in Accured Expenses over 5 years: stood at $11.4 million in 2022, then tumbled by 170.18% to -$8.0 million in 2023, then advanced by 3.75% to -$7.7 million in 2024, then surged by 223.38% to $9.5 million in 2025, then tumbled by 454.74% to -$33.7 million in 2026.
• Business Quant data shows AVNS's Change in Accured Expenses at -$33.7 million in Q1 2026, $9.5 million in Q4 2025, and -$400000.0 in Q3 2025.